Table 1.
Regimens of chemoradiotherapy for esophageal cancer
| Reference (first author) | Target | Chemoradiation or Chemoradiation + Surgery | Chemotherapy regimen (/m2) | Phase | Cases, n | Median overall survival (mo) | Survival rate (%) |
|---|---|---|---|---|---|---|---|
| Herskovic23 |
Esophageal cancer (SCC, AC) Stage IIB‐IIIA |
Chemoradiation 50 Gy |
F: 1000 (days 1‐4, 29‐33, 50‐53, 71‐74) C: 75 (weekly) |
III | 61 | 12.5 | — |
| Shapiro24 |
Esophageal cancer and junctional cancer (SCC, AC) Stage IIB‐IIIA |
Chemoradiation + Surgery 41.4 Gy |
Carboplatin (AUC 2 mg/mL/min) P: 50/days 1,8,15,22.29 |
III | 178 | 48.6 | 5 y OS (47) |
| Nomura30 |
Esophageal cancer (SCC) Stage II, III |
Chemoradiation 60 Gy |
F: 400 (days 1‐5, 8‐12) C: 40 (day 1, 8)/5 wks |
II | 73 | ― | 5 y PFS (38.3) |
| Bedenne31 |
Esophageal cancer (SCC) Stage III, IV |
Chemoradiation 61 Gy |
F: 800 (days 1‐5) C: 15 (day 1‐5)/3 wks |
― | 130 | ― | 2 y OS (40) |
| Bedenne31 |
Esophageal cancer (SCC) Stage III, IV |
Chemoradiation + Surgery for clinical response cases 46 Gy |
F: 800 (days 1‐5) C: 15 (day 1‐5)/3 wks |
― | 129 | — | 2 y OS (34) |
| Vincent32 |
Esophageal cancer (SCC) Stage III, IV |
Chemoradiation + Surgery for no clinical response cases 46 Gy |
F: 800 (days 1‐5) C: 15 (day 1‐5)/3 wks |
— | 111 | 17.0 | ― |
| Suntharalingam33 |
Esophageal cancer (SCC, AC) Non‐operable |
Chemoradiation 50.4 Gy |
P: 25 (day 1)/weekly C: 50 (day 1)/weekly Cet: 400 (day 1) 250/weekly |
III | 159 | ― | 3 y OS (34) |
AC, adenocarcinoma; C, cisplatin; Cet, cetuximab; F, fluorouracil; OS, overall survival; P, paclitaxel; PFS, progression free survival; SCC, squamous cell carcinoma; ―, not available.